|
28 Mar 2025 |
Abbott
|
Consensus Share Price Target
|
30720.55 |
29838.57 |
- |
-2.87 |
buy
|
|
|
|
|
17 Nov 2022
|
Abbott
|
ICICI Direct
|
30720.55
|
21725.00
|
19493.95
(57.59%)
|
Target met |
Hold
|
|
|
|
|
15 Nov 2022
|
Abbott
|
ICICI Securities Limited
|
30720.55
|
20523.00
|
19651.45
(56.33%)
|
Target met |
Hold
|
|
|
Abbott India’s (Abbott) Q2FY23 performance beat our estimates on the profitability front while revenues were largely in-line.
|
|
16 Aug 2022
|
Abbott
|
ICICI Direct
|
30720.55
|
21140.00
|
19069.75
(61.10%)
|
Target met |
Hold
|
|
|
|
|
12 Aug 2022
|
Abbott
|
Axis Direct
|
30720.55
|
20800.00
|
18793.35
(63.47%)
|
Target met |
Buy
|
|
|
Abbott India's strategy of Beyond the Pill' comprising awareness, diagnosis, treatment and compliance for consumers is expected to deliver continued growth for the business. Therefore, we maintain a BUY rating on the stock with a Target Price of Rs 20,800/share.
|
|
11 Aug 2022
|
Abbott
|
ICICI Securities Limited
|
30720.55
|
19478.00
|
19604.20
(56.70%)
|
Target met |
Hold
|
|
|
Abbott India’s (AIL) Q1FY23 performance was below our estimate on the profitability front.
|
|
18 May 2022
|
Abbott
|
Axis Direct
|
30720.55
|
20000.00
|
17875.55
(71.86%)
|
Target met |
Buy
|
|
|
We maintain a BUY rating on the stock with a Target Price of Rs 20,000/share.
|
|
18 May 2022
|
Abbott
|
ICICI Direct
|
30720.55
|
20560.00
|
17875.55
(71.86%)
|
Target met |
Buy
|
|
|
|
|
11 Feb 2022
|
Abbott
|
ICICI Securities Limited
|
30720.55
|
19840.00
|
16537.05
(85.77%)
|
Target met |
Buy
|
|
|
Abbott's top 10 brands - (Mixtard, Thyronorm, Novomix, Udiliv, Duphaston) together posted revenue CAGR of ~7% MAT, December 2018-22 Abbott has 140+ brands in segments of women's health, gastroenterology,...
|
|
10 Feb 2022
|
Abbott
|
Axis Direct
|
30720.55
|
20000.00
|
16615.00
(84.90%)
|
Target met |
Buy
|
|
|
The company is expected to report Revenue/PAT CAGR of 11.1% and 11.3% 0ver FY21-FY24E backed by stable sales in the Duphaston brand, an increase in volume in the Thyronorm brand, and a pick-up in the IPM growth. Therefore, we recommend a BUY rating on the stock with a Target Price of Rs 20,000/share
|
|
10 Jan 2022
|
Abbott
|
Axis Direct
|
30720.55
|
20000.00
|
18314.05
(67.74%)
|
Target met |
Buy
|
|
|
We recommend BUY with a TP of Rs 20,000/share.
|